Daily Cosmetic Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
Analyzed 23 papers and selected 3 impactful articles.
Selected Articles
1. Adipose-derived stem cell peptide 5 alleviates hypertrophic scarring through targeting pyruvate carboxylase or p50 to coordinate PI3K/AKT/mTOR-autophagy and NF-κB/IL-6 signaling.
ADSCP5 reduced collagen gene expression and downregulated p-PI3K, p-AKT, p-mTOR, and p-p65 in hypertrophic scar fibroblasts while lowering IL-6 transcription. Mechanistically, ADSCP5 directly bound pyruvate carboxylase (downregulated) or NF-κB p50 (upregulated), inducing ROS and autophagy and modulating macrophage-fibroblast crosstalk and angiogenesis. In rabbit and porcine scar models, ADSCP5 decreased collagen deposition and scar hyperplasia with increased CD68 and reduced VEGFA, CD34, and p62.
Impact: Identifying a bioactive peptide that directly targets metabolic and inflammatory nodes to curb fibrosis is a notable mechanistic advance with clear translational promise for scar prevention and treatment.
Clinical Implications: If validated in humans, ADSCP5 could become an adjuvant or prophylactic anti-scar therapy alongside surgery, silicone, laser, or corticosteroids, particularly for high-risk hypertrophic scarring.
Key Findings
- ADSCP5 suppressed COL1A1, COL1A2, COL3A1 and ACTA2 in hypertrophic scar fibroblasts without impairing proliferation, apoptosis, or migration.
- ADSCP5 reduced p-PI3K, p-AKT, p-mTOR, and p-p65 levels and decreased IL-6 transcription, indicating coordinated repression of PI3K/AKT/mTOR and NF-κB signaling.
- Direct binding to pyruvate carboxylase (downregulation) or NF-κB p50 (upregulation) mediated the anti-fibrotic effects; rescue assays confirmed target specificity.
- ADSCP5 induced ROS and autophagy (reduced p62) and exerted antiangiogenic effects (decreased VEGFA and CD34) while modulating macrophage-fibroblast crosstalk (increased CD68).
- In rabbit and porcine scar models, ADSCP5 reduced collagen deposition and scar hyperplasia.
Methodological Strengths
- Mechanistic validation with direct target binding and rescue assays
- Multi-system evaluation including human cells and rabbit/porcine scar models
Limitations
- Preclinical data without human trials; dosing, delivery, and safety profiles remain undefined
- Sample sizes and duration of in vivo assessments are not specified in the abstract
Future Directions: Define pharmacokinetics/toxicology, optimize delivery (e.g., topical depot or hydrogel), and proceed to early-phase trials using objective scar outcomes and biomarker endpoints.
BACKGROUND: Hypertrophic scars are a major clinical challenge with limited treatments. Adipose-derived stem cells (ADSCs) play an important role in inhibiting pathological scar formation. However, the underlying mechanisms remain unclear. In this study, we aimed to investigate the function, mechanism, and therapeutic potential of adipose-derived stem cell peptide 5 (ADSCP5), a novel peptide from adipose-derived stem cell-conditioned medium. METHODS: We used RESULTS: In hypertrophic scar fibroblasts, ADSCP5 significantly downregu
2. TRIM9 regulates the proliferation and apoptosis of dermal papilla cells by activating the Wnt/β-catenin signaling pathway to improve androgenetic alopecia.
TRIM9 expression was decreased in AGA. Overexpression of TRIM9 promoted hair growth in DHT-induced AGA mice, enhanced proliferation and reduced apoptosis of human dermal papilla cells, and upregulated β-catenin signaling. Mechanistically, TRIM9 competed with β-TrCP to inhibit β-TrCP-mediated ubiquitination and degradation of β-catenin, and Wnt inhibition (XAV939) attenuated these effects.
Impact: This work uncovers a previously unrecognized E3 ligase-based control point over β-catenin in dermal papilla cells, defining TRIM9 as a potential therapeutic target for androgenetic alopecia.
Clinical Implications: Targeting TRIM9-β-TrCP-β-catenin interactions could inspire new topical or gene-based therapies for hair loss, complementing current androgen or vasodilator approaches.
Key Findings
- TRIM9 expression is downregulated in androgenetic alopecia models.
- TRIM9 overexpression promotes hair growth in DHT-induced AGA mice and increases hDPC proliferation while inhibiting apoptosis.
- TRIM9 activates Wnt/β-catenin signaling; XAV939 attenuates TRIM9-induced effects, supporting pathway specificity.
- TRIM9 competes with β-TrCP, reducing β-TrCP–mediated ubiquitination and degradation of β-catenin.
Methodological Strengths
- Mechanistic dissection with co-immunoprecipitation and ubiquitination assays
- In vivo validation in DHT-induced AGA mouse model alongside human DPC assays
Limitations
- Preclinical study lacking human clinical data; magnitude and durability of effect in humans unknown
- Potential overexpression artifacts; endogenous modulation and safety require evaluation
Future Directions: Develop small molecules or biologics to modulate TRIM9 activity, assess topical delivery to follicles, and test efficacy/safety in early-phase human trials with trichoscopic endpoints.
BACKGROUND AND PURPOSE: Dermal papilla cells (DPCs) are signaling hubs for hair follicle growth and play a critical role in hair growth in patients with androgenetic alopecia (AGA). TRIM9, a tripartite motif (TRIM)-family E3 ubiquitin ligase, regulates cell differentiation, proliferation, and apoptosis. This study aimed to investigate the effects of TRIM9 on the proliferation and apoptosis of DPCs. METHODS: AGA mouse and cellular models were induced by dihydrotestosterone (DHT) treatment to conduct e
3. A Cannula-Based Sequential Injection Protocol for Non-surgical Rhinoplasty in East Asian Patients.
In 528 East Asian patients, a predefined cannula-based sequence (tip via fibrous septal deposition, then dorsum and glabellar triangle) yielded significant 3D anthropometric gains at 9 months and broad improvements across FACE-Q domains. No vascular events occurred; transient erythema resolved conservatively.
Impact: This large dual-center series standardizes an anatomy-driven, layer-specific approach with objective 3D outcomes and patient-reported benefits, informing safer, predictable non-surgical rhinoplasty in Asian noses.
Clinical Implications: Adopting a tip–dorsum–glabella cannula sequence with high G' HA and fibrous septal tip support may enhance aesthetic outcomes and reduce vascular risk in East Asian non-surgical rhinoplasty.
Key Findings
- Significant 3D improvements at 9 months: nasal length (+2.62 mm), tip projection (+3.69 mm), nasolabial angle (+5.7°), nasofrontal angle (−9.4°), all p < 0.001.
- FACE‑Q showed marked gains in satisfaction (+44.4), social function (+26.2), psychological well‑being (+28.1), and reduced distress (−39.4), all p < 0.001.
- No vascular complications; 11 cases of transient erythema resolved with conservative measures.
- A standardized, sequential cannula technique emphasizing fibrous septal tip augmentation was feasible across a high-volume East Asian cohort.
Methodological Strengths
- Large dual-center cohort with objective 3D photogrammetry and validated FACE-Q
- Predefined, anatomy-driven sequential protocol
Limitations
- Retrospective design without a comparator group limits causal inference
- Follow-up limited to 9 months; durability beyond this period is unknown
Future Directions: Prospective, multicenter studies with standardized safety monitoring and longer follow-up to compare cannula vs needle and sequence variations; cost-effectiveness and training assessments.
INTRODUCTION: Non‑surgical rhinoplasty is increasingly popular for nasal augmentation in East Asian patients. However, a standardized, anatomy‑driven protocol for the sequential and layered correction of the nasal tip, dorsum, and glabellar complex-key aesthetic units in the Asian nose-is still lacking. MATERIALS AND METHODS: In this dual‑center retrospective study, 528 East Asian patients (490 females, 38 males; mean age 27.7 years) underwent non‑surgical rhinoplasty between 2020 and 2024. A high‑G' hyal